McSally Sides With Corporate Backers On Medicare Negotiation For Lowering Drug Prices
The pharma-linked U.S. Chamber of Commerce is campaigning against reforms to lower the cost of prescription drugs, including Medicare price negotiation
The same group has also announced nearly $1 million to boost McSally’s 2020 election
PHOENIX — Martha McSally and a pharma-linked corporate interest group spending nearly $1 million to keep her in the U.S. Senate are aligned in their opposition to letting Medicare negotiate for lower prescription drug costs — a key reform that’s part of H.R. 3, which was today passed in the U.S. House of Representatives.
Who would oppose such a thing?
For one: the U.S. Chamber of Commerce, a Big Pharma-linked corporate interest group that has already announced nearly $1 million in TV ads to support Martha McSally’s 2020 campaign.
The U.S. Chamber of Commerce is publicly campaigning against H.R. 3 and Medicare drug price negotiation. The groups says that it “strongly opposes” the measure, which it claims sets a “dangerous precedent.”Martha McSally — like her corporate backers — opposes Medicare drug price negotiation, which is bad for Arizonans, but great news for health care and pharmaceutical corporations that profit off jacking up prices without consequences.